Today assays are available to detect a humoral immune response against alpha-methyl-acyl-CoA racemase, which may have the potential to complement PSA screening in identifying patients with clinically significant prostate cancer (Sreekumar et al. 2004). This evidence concerns the gene KLK3 and prostate cancer.